Wattacheril J. Nonalcoholic steatohepatitis (NASH): Diagnosis, treatment, and implications.Clin Liver Dis. 2018;22(1):1-10. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease.J Clin Endo...
非酒精性脂肪性肝病(nonalcoholic fatty liver disease, NAFLD)是目前最常见的慢性肝病之一,指除酒精和其他对肝脏有明确损害因素所引起的,肝脏内脂质过度沉积的疾病,包括单纯性脂肪肝(nonalcoholic fatty liver, NAFL)、非酒精性脂肪性肝炎(nonalcoholic steatohepatitis, NASH)及相关肝硬化。其中,NASH是NAFLD恶化的关键...
4. van de Wiel, et al. Identification of FDA-approved drugs targeting the Farnesoid X Receptor. Sci Rep 9, (2019).5. Xu, X. et al. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduction and Targeted Therapy v...
非酒精性脂肪性肝炎(NASH)是NAFLD的一种严重类型。 值得关注的是,2020年国际医学专家们达成共识,用代谢性相关脂肪肝病(Metabolic Associated Fatty Liver Disease, MAFLD)来替代NAFLD,改用肯定性的诊断标准。对于存在脂肪肝证据的患者,只要合并超重/肥胖、2型糖尿病、代谢功能障碍等任一条件即可诊断为MAFLD。 NAFLD和M...
2020年,悉尼大学Mohammed Eslam教授建议将NAFLD更名为代谢相关脂肪性肝病(metabolic-associated fattyliver disease, MAFLD)。 目前越来越多科学家支持这一改名,认为NAFLD不仅仅是肝病,而是一种涉及全身代谢疾病的肝脏表征。 疾病谱:非酒精性脂肪性肝病(NAFLD):大泡性肝脂变伴或不伴有轻度小叶内炎症或气球样变。肝病进展...
值得关注的是,2020年国际医学专家们达成共识,用代谢性相关脂肪肝病(Metabolic Associated Fatty Liver Disease, MAFLD)来替代NAFLD,改用肯定性的诊断标准。对于存在脂肪肝证据的患者,只要合并超重/肥胖、2型糖尿病、代谢功能障碍等任一条件即可诊断为MAFLD。
Non-alcoholic fatty liver disease (NAFLD) has evolved as the most common form of chronic liver disease in children and has become a serious public health issue. As in adults, NAFLD in children is tightly associated with obesity, insulin resistance, and a number of obesity-related metabolic ...
1. Targeted therapeutics and novel signaling pathways in non alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) 2. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease 3. Targeting fibrosis: mech...
liver disease and hepatocellular carcinoma. To a certain extent, that is true. But NAFLD is associated with obesity, which is a global epidemic, so now there is very clear data showing that all over the world, there ...
2023年的EASL会议上,来自世界各地的多个肝脏协会宣布采用“代谢相关脂肪性肝病(Metabolic associated fatty liver disease,MAFLD)”取代现有命名“非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)”的立场声明。这意味着,影响着全球近10亿人的疾病将跨入新时代。